Seeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer

Tanios Bekaii-Saab, Christina Wu

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Combinations of fluoropyrimidines with oxaliplatin or irinotecan plus a biologic agent are standard treatments for metastatic colorectal cancer (mCRC). Recent approvals of first-line cetuximab, second-line ziv-aflibercept, and regorafenib as salvage therapy have increased the complexity of the treatment armamentarium. To define optimal regimens, we systematically reviewed combination chemotherapy trials (N= 83). Descriptive analyses focusing on fluoropyrimidine formulation, oxaliplatin vs irinotecan combinations, and compatibility with biologics indicated the following: infusional 5-fluorouracil (5-FU) yielded better efficacy and safety than bolus 5-FU. Capecitabine had similar outcomes and better safety than 5-FU with oxaliplatin but not irinotecan. First-line oxaliplatin and irinotecan appeared equivalent. Antiangiogenics, such as bevacizumab and ziv-aflibercept, and epidermal growth factor receptor-targeted monoclonal antibodies cetuximab and panitumumab further improved efficacy. The treatment landscape for mCRC has become complex, and we are approaching individualized therapy based on predictive factors, including KRAS mutational status. Appropriate administration of chemotherapy/biologic combinations is critical.

Original languageEnglish (US)
Pages (from-to)9-34
Number of pages26
JournalCritical Reviews in Oncology/Hematology
Volume91
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

oxaliplatin
irinotecan
Combination Drug Therapy
Colorectal Neoplasms
Fluorouracil
Safety
Biological Products
Salvage Therapy
Biological Factors
Therapeutics
Epidermal Growth Factor Receptor
Monoclonal Antibodies
Forests

Keywords

  • Bevacizumab
  • Cetuximab
  • Chemotherapy regimen sequencing
  • FOLFIRI
  • FOLFOX
  • Irinotecan
  • Metastatic colorectal cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

@article{5481127865264d8fb0889fe548f2b3b9,
title = "Seeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer",
abstract = "Combinations of fluoropyrimidines with oxaliplatin or irinotecan plus a biologic agent are standard treatments for metastatic colorectal cancer (mCRC). Recent approvals of first-line cetuximab, second-line ziv-aflibercept, and regorafenib as salvage therapy have increased the complexity of the treatment armamentarium. To define optimal regimens, we systematically reviewed combination chemotherapy trials (N= 83). Descriptive analyses focusing on fluoropyrimidine formulation, oxaliplatin vs irinotecan combinations, and compatibility with biologics indicated the following: infusional 5-fluorouracil (5-FU) yielded better efficacy and safety than bolus 5-FU. Capecitabine had similar outcomes and better safety than 5-FU with oxaliplatin but not irinotecan. First-line oxaliplatin and irinotecan appeared equivalent. Antiangiogenics, such as bevacizumab and ziv-aflibercept, and epidermal growth factor receptor-targeted monoclonal antibodies cetuximab and panitumumab further improved efficacy. The treatment landscape for mCRC has become complex, and we are approaching individualized therapy based on predictive factors, including KRAS mutational status. Appropriate administration of chemotherapy/biologic combinations is critical.",
keywords = "Bevacizumab, Cetuximab, Chemotherapy regimen sequencing, FOLFIRI, FOLFOX, Irinotecan, Metastatic colorectal cancer, Oxaliplatin",
author = "Tanios Bekaii-Saab and Christina Wu",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.critrevonc.2014.01.001",
language = "English (US)",
volume = "91",
pages = "9--34",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Seeing the forest through the trees

T2 - A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer

AU - Bekaii-Saab, Tanios

AU - Wu, Christina

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Combinations of fluoropyrimidines with oxaliplatin or irinotecan plus a biologic agent are standard treatments for metastatic colorectal cancer (mCRC). Recent approvals of first-line cetuximab, second-line ziv-aflibercept, and regorafenib as salvage therapy have increased the complexity of the treatment armamentarium. To define optimal regimens, we systematically reviewed combination chemotherapy trials (N= 83). Descriptive analyses focusing on fluoropyrimidine formulation, oxaliplatin vs irinotecan combinations, and compatibility with biologics indicated the following: infusional 5-fluorouracil (5-FU) yielded better efficacy and safety than bolus 5-FU. Capecitabine had similar outcomes and better safety than 5-FU with oxaliplatin but not irinotecan. First-line oxaliplatin and irinotecan appeared equivalent. Antiangiogenics, such as bevacizumab and ziv-aflibercept, and epidermal growth factor receptor-targeted monoclonal antibodies cetuximab and panitumumab further improved efficacy. The treatment landscape for mCRC has become complex, and we are approaching individualized therapy based on predictive factors, including KRAS mutational status. Appropriate administration of chemotherapy/biologic combinations is critical.

AB - Combinations of fluoropyrimidines with oxaliplatin or irinotecan plus a biologic agent are standard treatments for metastatic colorectal cancer (mCRC). Recent approvals of first-line cetuximab, second-line ziv-aflibercept, and regorafenib as salvage therapy have increased the complexity of the treatment armamentarium. To define optimal regimens, we systematically reviewed combination chemotherapy trials (N= 83). Descriptive analyses focusing on fluoropyrimidine formulation, oxaliplatin vs irinotecan combinations, and compatibility with biologics indicated the following: infusional 5-fluorouracil (5-FU) yielded better efficacy and safety than bolus 5-FU. Capecitabine had similar outcomes and better safety than 5-FU with oxaliplatin but not irinotecan. First-line oxaliplatin and irinotecan appeared equivalent. Antiangiogenics, such as bevacizumab and ziv-aflibercept, and epidermal growth factor receptor-targeted monoclonal antibodies cetuximab and panitumumab further improved efficacy. The treatment landscape for mCRC has become complex, and we are approaching individualized therapy based on predictive factors, including KRAS mutational status. Appropriate administration of chemotherapy/biologic combinations is critical.

KW - Bevacizumab

KW - Cetuximab

KW - Chemotherapy regimen sequencing

KW - FOLFIRI

KW - FOLFOX

KW - Irinotecan

KW - Metastatic colorectal cancer

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=84901589715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901589715&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2014.01.001

DO - 10.1016/j.critrevonc.2014.01.001

M3 - Review article

C2 - 24534706

AN - SCOPUS:84901589715

VL - 91

SP - 9

EP - 34

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -